Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series

References

• 1 Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract. Res. Clin. Gastroenterol. 28(5), 753–770 (2014).
  MedlineGoogle Scholar
• 2 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 3 Cheng AL, Kang YK, Chen ZD et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
  Medline CASGoogle Scholar
• 4 Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015).
  MedlineGoogle Scholar
• 5 Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375–384 (2015).
  Medline CASGoogle Scholar
• 6 Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl J. Med. 377(20), 1919–1929 (2017).
  Medline CASGoogle Scholar
• 7 El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).
  Medline CASGoogle Scholar
• 8 Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 389(10064), 56–66 (2017).
  Medline CASGoogle Scholar
• 9 Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology 92(Suppl. 1), 50–62 (2017).
  MedlineGoogle Scholar
• 10 Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-09-1624 (2009).
  MedlineGoogle Scholar
• 11 Hodi FS, Hwu WJ, Kefford R et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34(13), 1510–1517 (2016).
  Medline CASGoogle Scholar
• 12 Nishino M, Giobbie-Hurder A, Manos MP et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin. Cancer Res. 23(16), 4671 (2017).
  Medline CASGoogle Scholar
• 13 Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int. J. Immunopharmacol. 58, 125–135 (2018).
  CASGoogle Scholar
• 14 Solinas C, Porcu M, Hlavata Z et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit. Rev. Oncol. Hematol. 120, 13–21 (2017).
  MedlineGoogle Scholar
• 15 Seymour L, Bogaerts J, Perrone A et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18(3), e143–e152 (2017).
  MedlineGoogle Scholar
• 16 Chubachi S, Yasuda H, Irie H et al. A case of non-small cell lung cancer with possible ‘disease flare’ on nivolumab treatment. Case Rep. Oncol. Med. 2016, 1075641 (2016).
  MedlineGoogle Scholar
• 17 Denaro N. Hyperprogression after immunotherapy in HNC: literature review and our experience. Int J Radiol Radiat Oncol. 4(1), 001–002 (2018).
  Google Scholar
• 18 Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M. Hyperprogressive disease in anorectal melanoma treated by PD-1 inhibitors. Front. Immunol. 9, 797 (2018). DOI:10.3389/fimmu.2018.00797.
  Google Scholar
• 19 Occhipinti M, Falcone R, Onesti CE, Marchetti P. Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report. Drug Saf. Case Rep. 5(1), (12), (2018). DOI: 10.1007/s40800-018-0078-z.
  MedlineGoogle Scholar
• 20 Shinozaki T, Iwami E, Ikemura S et al. A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. BMC Cancer 18(1), (620), (2018). 10.1186/s12885-018-4549-5.
  MedlineGoogle Scholar
• 21 Yoshida T, Furuta H, Hida T. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. Med. Oncol. 34(3), 34 (2017).
  MedlineGoogle Scholar
• 22 Champiat S, Dercle L, Ammari S et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 23(8), 1920–1928 (2017).
  Medline CASGoogle Scholar
• 23 Saada-Bouzid E, Defaucheux C, Karabajakian A et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 28(7), 1605–1611 (2017).
  Medline CASGoogle Scholar
• 24 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res. 23(15), 4242–4250 (2017).
  Medline CASGoogle Scholar
• 25 Weiss GJ, Beck J, Braun DP et al. Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin. Cancer Res. 23(17), 5074–5081 (2017).
  Medline CASGoogle Scholar
• 26 Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H. Hyperprogressive disease in the irradiation field after a single dose of nivolumab for gastric cancer: a case report. Case Rep. Oncol. 11(1), 143–150 (2018).
  MedlineGoogle Scholar
• 27 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin. Mol. Hepatol. 22(1), 7–17 (2016).
  MedlineGoogle Scholar
• 28 Hepatobiliary Cancers. NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines) (5 June 2018), (2018).
  Google Scholar
• 29 Sangro B, Park JW, Cruz CMD et al. A randomized, multicenter, Phase 3 study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma: CheckMate-459. J. Clin. Oncol. 34(15 suppl 1), TPS4147 (2016).
  Google Scholar
• 30 Peng W, Liu C, Xu C et al. PD-1 blockade enhances T cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. doi:10.1158/0008-5472.Can-12-1187 (2012).
  Google Scholar
• 31 Waight JD, Netherby C, Hensen ML et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123(10), 4464–4478 (2013).
  Medline CASGoogle Scholar
• 32 Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282(28), 20059–20063 (2007).
  Medline CASGoogle Scholar
• 33 Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659), 844–848 (2004).
  Medline CASGoogle Scholar
• 34 Sakai S, Kauffman KD, Sallin MA et al. CD4 T cell-derived IFN-γ plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 12(5), e1005667 (2016).
  MedlineGoogle Scholar
• 35 Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15(7), 409 (2015).
  Medline CASGoogle Scholar
• 36 Koyama S, Akbay EA, Li YY et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).
  Medline CASGoogle Scholar
• 37 Kleffel S, Posch C, Barthel SR et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162(6), 1242–1256 (2015).
  Medline CASGoogle Scholar